Senseonics’ New Program Geared Towards Patients with High-Deductible Insurance Plans

New program called Eversense Bridge for patients who carry a high-deductible insurance plans.

Image: Senseonics

Senseonics, a company well-known for its continuous glucose monitoring (CGM) system announced a new program called Eversense Bridge for patients who carry a high-deductible insurance plans or patients whose insurance plans do not cover the full cost of CGM.

Patients are charged $99 for the Eversense CGM system through the new program on top of the cost of the sensor placement by their provider. Patients will be able to get their second sensor for the same price, although the price will increase afterward, reports MobiHealthNews.

“As with any new medical device or drug, we knew it would take some time for insurance companies to add Eversense CGM to their covered diabetes management options,” Mike Gill, VP and general manager for the US region at Senseonics, told MobiHealthNews in an email. “We were pleased to have many insurers cover Eversense from the beginning, but there are many other people that need this technology and are being denied coverage for this revolutionary long-term technology, and we wanted to help them while they await favorable policy decisions from their insurers.”

In the United States more than 30 million people are living with diabetes. Unlike some chronic diseases, managing diabetes is extremely complex. Successful diabetes management requires creating new habits around medication adherence and glucose monitoring, change diets dramatically, exercise, and more.

Several companies including Abbott, Dexcom and Medtronic are working on Continuous Glucose Monitoring (CGM) systems.

The Eversense CGM system received FDA approval in July after waiting more than two-and-a-half years for the clearance.

“Eversense provides people with diabetes the freedom from self-insertions and has a removable transmitter can be taken off and on for those times they don’t want anything on their body,” Gill wrote. “All glucose readings are sent directly to a smartphone, so no additional receiver is required. The system also has on-body vibe alerts and audible alerts to warn if glucose levels are too high or about to go low, which is especially important during the night.”

Senseonics recently announced that Eversense would be integrating with Glooko’s diabetes management system.

Sam Draper
March 26, 2019

Innovation of the Month

Do you want to discover more, visit the website
Visit Website

Other news

January 2024: Hydrogel-Free Flexcon® Omni-Wave™ for Biosensing

Dry electrode technology saves time and money for manufacturers while improving patient comfort!

Theranica Wins FDA Approval for Its Wearable Nerivio to Treat Acute Migraine in Adolescents

Theranica, a prescribed digital therapeutics (PDT) company developing advanced electroceuticals...

More On Samsung’s New XR Headset

Samsung’s XR project will also involve service collaborations with Meta and Microsoft.

INNOVO: Non-Invasive Wearable to Treat Stress Urinary Incontinence in Women

INNOVO is an FDA-cleared non-invasive wearable to treat Stress Urinary Incontinence in women.
Discover more